Drugs / SAB-301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02788188 | May 2016 → Apr 2018 | Middle East respiratory syndrome | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-05-01 | SAb Biotherapeutics, Inc. | Results Convalescent Serum Lines Up As First-Choice Treatment For Coronavirus sab.bio ↗
In a placebo-controlled phase 1 trial in 38 healthy volunteers, SAB-301 demonstrated a placebo-like safety profile and, importantly, those who received the cocktail did not develop an antibody response against any of its components, Sullivan says. |
| 2018-01-10 | SAb Biotherapeutics, Inc. | Results First Treatment For MERS Appears Safe In NIH Phase I Clinical Trial sab.bio ↗
SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, announced its anti-MERS immunotherapy (SAB-301) appears safe in a Phase I Clinical Trial. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-05-01 | SAb Biotherapeutics, Inc. | Convalescent Serum Lines Up As First-Choice Treatment For Coronavirus sab.bio ↗ |
| 2018-01-10 | SAb Biotherapeutics, Inc. | First Treatment For MERS Appears Safe In NIH Phase I Clinical Trial sab.bio ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAB-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02788188 ↗ |
| Modality | Protein / enzyme biologic | “a fully human polyclonal IgG antibody (SAB-301)” PMID 29329957 ↗ Jan 2018 |
| Route | Intravenous | “The drug product will be administered intravenously” NCT02788188 ↗ |